Ginkgo's Counteroffensive: Taking CRO Work Back from China with Autonomous Labs
Q2 2026 sees Ginkgo pivot from lab services to selling automation and undercutting offshore CROs with ADME-One, backed by new academic deals.
DNA · Earnings Call · 2026-08-05
A Pivot from Services to Selling the Lab
Ginkgo Bioworks reported a 48% year-over-year revenue decline in Q2 2026, but the strategic narrative has sharply pivoted. The company is no longer merely an outsourced R&D shop; it's positioning itself as the answer to the offshoring of biology. CEO Jason Kelly framed the quarter around a new imperative: offshore CROs have hollowed out U.S. bench science, and Ginkgo's autonomous labs are the counterweight.
The bench is 95% plus of the $60 billion to $80 billion a year that pharma companies spend on research... and the $40 billion a year like the NIH spends on doing research laboratory work. And so all that money is going towards the benches and almost none of it today is going to robotics because not because we don't know about robots, but because the robotic systems so far have not been flexible enough to do science.
To attack this space, Ginkgo launched ADME-One, a standard panel of five Tier 1 assays for small-molecule drug candidates. Kelly's pitch is direct: “You can get them from Western CRO vendors for $2,000 to $5,000 for the panel or from Chinese CRO vendors for $1,000 to $2,500 for the panel. Or you can get them from Ginkgo Datapoints for $199.” (inline quote from 8281579607272990112). He goes further: “We think we stand up very well to WuXi in terms of technical capability and throughput and we kick their butt on price.” — Jason Kelly, Co-Founder and Chief Executive Officer · 2026-08-05 The company has already validated the assays against external vendors and published a 320-compound LOPAC dataset, inviting customers to compare. This is a direct attack on the economics that drove traditional CRO work to China.
Scaling the Autonomous Lab: Nebula and Academic Deals
The vehicle for this counterattack is Nebula, Ginkgo's autonomous lab in Boston, which now runs 105 RACs (Robotic Aided Cart systems). Kelly highlighted “we roughly doubled the size of the system... over a 3-week period” — Jason Kelly, Co-Founder and Chief Executive Officer · 2026-08-05 — a testament to the productization of what was once custom integration. More importantly, the lab is increasingly a revenue source. Ginkgo announced it was selected to build autonomous labs for MIT, Caltech, Maryland, and Northwestern, with the latter three funded through an NSF program and MIT via a separate grant. Kelly frames this as training the next generation of scientists: “getting autonomous labs in the hands of graduate students, people with my sort of training so that they're learning how to do science on top of robotics rather than how I was taught which was sort of slaving away at a lab bench doing experiments by hand.” — Jason Kelly, Co-Founder and Chief Executive Officer · 2026-08-05 The Genesis Mission, an OSTP initiative, is pouring $400 million into a national network of cloud laboratories, and Ginkgo is already building the first such system for Pacific Northwest National Lab.
This is a clear escalation from prior quarters. In late 2025, Kelly spoke of wanting to see “50-plus scientists internally at Ginkgo ordering simultaneously from our automation system in a single day” — Jason Kelly, Co-Founder and CEO · 2025-11-06 — an internal milestone. Now the focus is on outward sales, with a mix of equipment delivery and recurring service/SaaS revenue. CFO Steve Coen noted that for hardware deals, revenue is recognized at delivery, but services and software licensing follow.
Financial Discipline Amid Transformation
Financially, the company is in a familiar contraction. Total revenue in Q2 2026 was $20M, down 48% year-over-year (ex a $7.5M noncash item, ~42%). But management emphasized improvement in cash burn: “In the second half of this year, we intend to improve on that burn even further than we did in the first half of the year” — Jason Kelly, Co-Founder and Chief Executive Officer · 2026-08-05. Q2 cash burn was $45M, down from $38M a year ago (though that included a $14M payment to Google Cloud in Q1). The full-year 2026 cash burn guidance remains $125–150M, reaffirmed. The company holds $302M cash plus $87M restricted.
The strategic pivot is also reflected in the keyword trajectory. In prior calls, the conversation centered on autonomous labs and data generation. Now the vocabulary has shifted to “offshore CROs,” “traditional CRO,” and “ADME-One” — all among the top 10 keywords for this quarter. Kelly is explicit that this is a new business: “We launched a ServiceNow about 6 weeks ago called ADME-One... This is sort of a standard panel of 5 Tier 1 assays.” — Jason Kelly, Co-Founder and Chief Executive Officer · 2026-08-05 The company is also planning to bring chemical synthesis into the autonomous environment, attacking a bigger fraction of the CRO business.
From a competitive standpoint, this is a bold bet. Ginkgo is trading at roughly 2.7x revenue (down from 86x at peak) and still burning cash. But the combination of a scalable hardware platform, a radical price advantage on assays, and government tailwinds from the Genesis Mission makes this quarter stand out. As Kelly put it, “I think this is how the U.S. is going to bring back the world of Adams” — Jason Kelly, Co-Founder and Chief Executive Officer · 2026-08-05 — bringing manufacturing and science back onshore through automation, not protectionism. Whether it works remains to be seen, but the narrative has decisively changed.